Resumo

RICO-FONTALVO, Jorge et al. SGLT-2 inhibitors in Lupus Nephropathy. It could be considered an intervention of Nephroprotection. Rev. parag. reumatol. [online]. 2022, vol.8, n.2, pp.94-100. ISSN 2413-4341.  https://doi.org/10.18004/rpr/2022.08.02.94.

Abstract: Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune rheumatologic disorder. The kidneys are frequently affected organs. The usual treatment of lupus nephritis includes nephroprotective drugs, immunosuppressants, and immunomodulators. SGLT-2 inhibitors are drugs that initially arrived as antidiabetics. Important cardio and nephroprotective effects have been found even in nondiabetic patients. Experimental studies of lupus nephritis mentioned the expression of SGLT-2; therefore, this article aims to make an updated review of the evidence on the use of SGLT-2 inhibitors in patients with nephritis. Extensive clinical trials with SGLT-2 inhibitors have generally excluded these patients. The current evidence of the use of iSGLT-2 in lupus nephritis is quite limited and carries from small observational studies and case series, where there are benefits in reducing proteinuria. More trials are required to establish its long-term effects.

Palavras-chave : Systemic lupus erythematosus; Lupus nephropathy; SGLT2 inhibitors; Nephroprotection; Proteinuria.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )